Below are the first 10 and last 10 pages of uncorrected machine-read text (when available) of this chapter, followed by the top 30 algorithmically extracted key phrases from the chapter as a whole.
Intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text on the opening pages of each chapter. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
Do not use for reproduction, copying, pasting, or reading; exclusively for search engines.
OCR for page 21
Vaccine Safety Forum: Summaries of Two Workshops REFERENCES Braun MM, Ellenberg SS. Descriptive epidemiology of adverse events following immunizations: Reports to the Vaccine Adverse Event Reporting System (VAERS), 1991–1994. Journal of Pediatrics (in press). Classen JB, Classen DC. Timing of immunization alters risk of diabetes. Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 15–18, New Orleans. Washington D.C.: American Society of Microbiology, 1996. Farrington CP, Nash J, Miller E. Case series analysis of adverse reactions to vaccines: A comparative evaluation. American Journal of Epidemiology 1996; 143:1165–1173. Glasser JW, Myers RC, Siber GR, Rhodes PH, Chen RT, Wassilak SGF, Hadler SC. Use of vaccine adverse event reporting rates to validate pre-release laboratory tests and identify unusual vaccine lots. Unpublished abstract. Haber P, Gordon S, Eltermann D, House S, Chen RT. Assessing extent of misclassification of early Guillain-Barré syndrome after influenza vaccination, Vaccine Adverse Event Reporting System (abstract), U.S., 1990–1994. Pharmacoepidemiology and Drug Safety 1994; 3:S34. Institute of Medicine (IOM). Adverse Effects of Pertussis and Rubella Vaccines. Washington, D.C.: National Academy Press, 1991. IOM. Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality. Washington, D.C.: National Academy Press, 1994a. IOM. DPT Vaccine and Chronic Nervous System Dysfunction: A New Analysis. Washington, D.C.: National Academy Press, 1994b.
OCR for page 22
Vaccine Safety Forum: Summaries of Two Workshops IOM. Research Strategies for Assessing Adverse Events Associated with Vaccines: A Workshop Summary. Washington, D.C.: National Academy Press, 1994c. IOM. Options for Poliomyelitis Vaccination in the United States: Workshop Summary. Washington, D.C.: National Academy Press, 1996. Janoff EN, et al. Increased HIV-1 burden with immune activation following immunization with pneumococcal vaccine. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, (Abstract No. 1237). Washington, D.C.: American Society of Microbiology, 1995. Lasky T, Terracciano G, Chen R, et al. The association of GBS with the influenza vaccines of 1992–1993 and 1993–1994. Presentation to the Advisory Committee on Immunization Practices, February 12, 1997, Atlanta. Martin WJ, Ahmed KN, Zeng LC, Olsen JC, Seward JG, Seehrai JS. African green monkey origin of the atypical cytopathic ''stealth virus" isolated from a patient with chronic fatigue syndrome. Clinical and Diagnostic Virology 1995; 4:93–103. Martin WJ, Zeng LC, Ahmed K, Roy M. Cytomegalovirus-related sequence in an atypical cytopathic virus repeatedly isolated from a patient with chronic fatigue syndrome. American Journal of Pathology 1994; 145:440–451. O'Brien WA, et al. HIV-type 1 replication can be increased in peripheral blood of seropositive patients after influence vaccination. Blood 1995; 86:1082–1089. Rosenthal S, Chen RT. Reporting sensitivities of two passive surveillance systems for adverse events. American Journal of Public Health 1995; 85:1706–1709. Tasker S, et al. Effects of influenza vaccination in HIV infected patients: A double blinded placebo controlled trial. Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, (Abstract No. LB-11). Washington, D.C.: American Society of Microbiology, 1995. Wise RP. Medical review of vaccine safety reports. Presentation to the Vaccines and Related Biological Products Advisory Committee, August 24, 1994.
Representative terms from entire chapter: